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Material and Methods  
A549 (NSCLC) and 143B (osteosarcoma) were depleted 
from their mtDNA (ρ°) via ethidium bromide exposure. 
Cytoplasmic hybrids (cybrids) were produced by fusing 
the 143B-ρ° cell line with mtDNA derived from fibroblasts 
carrying an m.3243A>G mutation. All cells were 
metabolically characterized using the Seahorse XF96 
analyzer. Pharmacological OXPHOS inhibition was induced 
by either metformin or rotenone. CAIX, VEGF, HIF-1α and 
PHD2 mRNA expression upon hypoxia (0.2%, 16h) was 
determined by qPCR. CAIX and HIF-1α protein levels were 
determined by Western blotting. Reactive oxygen species 
levels (ROS) were measured using DHR flow cytometry. 
Tumor growth and hypoxic fraction (pimonidazole 
positivity) was monitored for xenografts generated from 
the cytoplasmic hybrids. 
Results  
Reduced (p<0.05) mitochondrial respiration and an 
increased glucose metabolism were observed in ρ° cell 
lines (<6% remaining mtDNA copy number) and in the 
cybrid cell lines (point mutation >94.5%). Upon hypoxia, 
OXPHOS inhibition resulted in decreased (p<0.05) CAIX 
(protein/mRNA), VEGF (mRNA) and HIF-1α (protein) 
expression levels. ROS and PHD2 levels could not explain 
these observations. Similar results were found upon 
pharmacological inhibition. In vivo, tumor take (>50 mm3) 
took longer for cybrid xenografts, but growth rates were 
similar compared to control tumors once established. 
Previously, it has been shown that HIF-1α is responsible 
for tumor establishment. In agreement, HIF-1α expression 
levels and the pimonidazole-positive hypoxic fraction 
were reduced for the cybrid xenografts. Most of the 
tumors established from the mutant cell line lost their 
m.3243A>G mutation in vivo, possibly explaining the 
delayed tumor take and the absence of an effect on 
growth rate. The presence of HIF-1α in cell lines with 
lower mutation percentage supports this observation.  
Conclusion  
Our results demonstrated that OXPHOS inhibition leads to 
a decreased HIF-1α stabilization and expression of 
downstream targets such as CAIX, VEGF and a reduced 
hypoxic fraction in vivo. Inhibition of mitochondrial 
function is therefore an interesting approach to increase 
therapeutic efficacy for radiation of hypoxic tumors.  
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Purpose or Objective  
Only recently, imaging and high-precision radiation 
devices for preclinical tumor mouse models have been 
developed. Image guided radiation therapy (IGRT) 
including innovative treatment planning techniques 
comparable to patients’ treatment can be achieved in a 
translational context.  
The present study aims to evaluate different treatment 
techniques and collimator shapes in planning related 
settings (contouring, fusion) for high-precision radiation 
therapy (RT) of an orthotopic pancreatic tumor mouse 
model. 
Material and Methods  
In an orthotopic pancreatic cancer model MRI-based 
radiation treatment planning was established. Two 
advanced radiation techniques (rotation and 3-
dimensional multifield RT) were performed and 
depending on the tumor volume different collimators 
(fixed sizes and variable) were used for subsequent 
irradiation with the SARRP system (Small Animal 
Radiation Research Platform, Xstrahl Ltd). Dose 
distributions in gross tumor volume (GTV) and organs at 
risk (OAR) were analyzed and compared for each 
treatment setting. 
Results  
Magnetic resonance imaging (MRI) detects gross tumor 
volume and organs at risk with improved soft tissue 
contrast. MRI-based 3D treatment planning allows an 
optimal sparing of normal tissue and maximum dose in 
the GTV, thus providing a perfect basis for an improved 
imaging in high-precision RT. All advanced radiation 
techniques (rotation and multifield) established in a 
preclinical tumor mouse model reflect clinical treatment 
plans of pancreatic cancer patients.  
Conclusion  
A MRI-based treatment planning and image guided high-
precision RT using different innovative radiation 
techniques was established in an orthotopic pancreatic 
tumor mouse model. The development of variable 
collimators in preclinical settings allows considering 
surrounding safety margins, perfect coverage of GTV, 
more flexibility of tumor shapes and optimal reflecting 
the clinical setting.  
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Purpose or Objective  
Neoadjuvant radiotherapy (NeoRT) improves tumor local 
control and facilitates tumor resection in many cancers. 
The timing between the end of the NeoRT and surgery is 
driven by the occurrence of side effects or the tumor 
downsizing. Some clinical studies demonstrated that the 
timing of surgery and the RT schedule influence tumor 
dissemination and subsequently patient overall survival 
(acta oncol 2006). Previously, we developed a pre-clinical 
model demonstrating an impact of NeoRT schedule and 
the timing of surgery on metastatic spreading 
(Oncotarget 2015). Here, we used functional MRI (fMRI) 
to record tumor microenvironment modifications after 
NeoRT. We aim to get non-invasive markers to establish 
the best timing to perform surgery and avoiding tumor 
spreading. 
Material and Methods  
Based on our NeoRT model, MDA-MB 231 and 4T1 cells 
were implanted in the flank of SCID and BalbC mice, 
respectively. We locally irradiated (PXI, X-Rad SmART) 
tumors with 2x5Gy and then surgically removed at 
different time points after RT. We acquired fMRI (9,4T 
Agilent) before and after RT. Diffusion Weighted (DW) -
MRI was performed every 2 days between RT and surgery. 
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For each tumor, we acquired 8 slices of 1 mm thickness 
and 0.5 mm gap with an "in plane voxel resolution” of 0.5 
mm. For DW-MRI, we performed FSEMS (Fast Spin Echo 
MultiSlice) sequences, with 9 different B-value (from 40 
to 1000) and B0, in the 3 main directions. We performed 
IVIM (IntraVoxel Incoherent Motion) analysis to obtain 
information on intravascular diffusion, related to 
perfusion (F: perfusion factor) and subsequently tumor 
vessels perfusion.  
Results  
With the MDA-MB 231, we observed a significant and 
transient increase (60% of the basal value (n=6, p<0,05)) 
of F and D* parameters related to perfusion. The other 
parameters of the DW-MRI, ADC and D presented no 
modification. We observed similar results with 4T1 cells, 
where F increased at day 3 (55% of the basal value, n=10, 
p<0,05) then returned to initial level. The difference in 
timing for the peak of F (day 6 vs day 3) could be related 
to the difference in tumor growth according to the cell 
line (four weeks for MDA-MB 231 cells vs one week for 
4T1 cells). We also observed a decrease of hypoxia 
(pimonidazole staining) when surgery was performed on 
the peak but vascular architecture was not affected. 
Moreover, performing surgery during F and D* peak, in 
the MDA-MB 231model, is associated with an increase of 
lung metastases: 115% and 187% compared to a surgery 
performed before or after the peak.  
Conclusion  
We demonstrated the feasibility of repetitive fMRI 
imaging in preclinical models after NeoRT. We showed a 
significant difference in perfusion-related parameters (D* 
and F) at a specific time point depending of tumor cells 
correlated with tumor metastases. We demonstrated the 
feasibility of Image Guided Surgery for decreasing tumor 
metastases after NeoRT. 
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Purpose or Objective  
To enhance tumor response and thus treatment outcome 
in radiation therapy, a dose prescription strategy is 
necessary to individualize radiation oncology. However, 
prediction of cell-specific survival prior to treatment is 
currently unavailable. Thus, we developed an approach 
to stratify patients by predicting individual radiation 
response based on cell survival. 
Material and Methods  
Based on a previously developed mechanistic radiation 
response model of DNA repair and cell survival (CS) 
prediction for normal tissue cells, we simulated measured 
radiobiological parameters (α and β) of 19 in vitro cancer 
cell lines (skin, lung, brain). The radiation model 
incorporated four cell-specific parameters: number of 
chromosomes, p53 mutation status, cell-cycle 
distribution and the effective genome size (GS). Only the 
first three input parameters were experimentally 
available; the latter was obtained by minimizing the 
difference between the simulated and measured α and β 
values. A parametrization of the GS as a function of the 
cells’ chromosome number and nucleus volume was 
proposed. The use of these input parameters was 
validated by comparing the simulated outcome of time-
dependent γH2AX data over 24h with independent 
experimental datasets. 
Results  
Overall good agreement between simulated and 
measured in vitro cancer CS curves was achieved (Fig. 1). 
The measured β values increased quadratically with the 
obtained GS (R2=0.81) irrespective of other cell-specific 
parameters (Fig. 2b). The measured α values increased 
linearly with GS manifesting different slopes 
distinguishable into the cells’ p53 mutation status (Fig. 
2a). Measured α and β values were predictable based on 
GS with a one-sigma uncertainty: σ=0.04Gy-1 for α and 
σ=0.01Gy-2 for β. The GS correlated (R2=0.70) with the 
number of chromosomes for all but four cell lines. The 
detailed cell-specific cell cycle distribution had a 
negligible impact on α and β. Measured time-dependent 
γH2AX data were consistent with the repair kinetics 
simulations (R2=0.95). 
 
Fig.1: Measured (symbols) and simulated (lines) survival 
curves for 3 cancer cell lines (green: A172 (p53wt), red: 
T98MG (p53mt), blue: LC1SQ (p53mt)); highlighted in Fig.2 
 
 
Fig.2: Measured α and β values as a function of simulated 
genome size: a) α increases linearly with genome size and 
can be stratified in two groups: p53wt, p53mt; b) β 
increases quadratically with genome size for all two 
groups. Highlight: see Fig.1 
